Hong Kong Pharmaceuticals Stock News

SEHK:1024
SEHK:1024Interactive Media and Services

Kuaishou Technology (SEHK:1024) Reports Weaker Profitability, Is The Selloff Too Harsh?

Kuaishou Technology (SEHK:1024) just released its second quarter and half year 2026 results, showing slightly higher sales but weaker net income and earnings per share. That shift in profitability is now in clear focus for investors. At a share price of HK$33.64, Kuaishou Technology has seen its 30 day share price return fall 25.28% and its year to date share price return fall 49.22%. The 1 year total shareholder return is down 52.16%, suggesting recent momentum has weakened as investors...
SEHK:1789
SEHK:1789Medical Equipment

Global Undervalued Small Caps With Insider Action To Enhance Your Portfolio

As global markets navigate mixed signals, with major U.S. indices like the S&P 600 for small-cap stocks experiencing some declines amid broader economic uncertainties, investors are keenly observing potential opportunities in undervalued segments. In this climate, small-cap stocks with notable insider activity can offer intriguing prospects for portfolio diversification and growth potential.
SEHK:6682
SEHK:6682Software

Phancy Group (SEHK:6682), What Is Behind The Fresh Attention?

Phancy Group (SEHK:6682) is back in focus after reporting half year 2026 earnings, with sales of CNY 3,765.29 million and net income of CNY 118.87 million, compared with a net loss a year earlier. The earnings swing has arrived alongside a sharp reset in sentiment, with Phancy Group’s share price down 36.61% year to date and the 1 year total shareholder return falling 49.66%. This comes even though the stock has gained 9.85% over the past week and rose 1.86% on the day of the results. Scan...
SEHK:2696
SEHK:2696Biotechs

Shanghai Henlius Biotech (SEHK:2696) Reports Strong Half Year Growth, Is It Overvalued?

Shanghai Henlius Biotech (SEHK:2696) drew fresh attention after reporting half year 2026 sales of CNY 3,588.23 million and net income of CNY 430.44 million, alongside a new Hong Kong principal business address. Shanghai Henlius Biotech’s recent half year update has come alongside a strong shift in market sentiment, with a 22.55% 1 month share price return and a 16.38% year to date share price return, even though the 1 year total shareholder return declined 11.43%. Spot fresh momentum in...
SEHK:152
SEHK:152Infrastructure

Shenzhen International Holdings (SEHK:152) Swung To A Half Year Loss, Is It 46% Undervalued?

What Shenzhen International Holdings’ Latest Half Year Earnings Reveal Shenzhen International Holdings (SEHK:152) reported half year 2026 earnings on August 28, with sales of HK$8,230.36 million and a shift from net income a year earlier to a net loss of HK$220.61 million. The swing to a HK$220.61 million loss appears to have coincided with pressure on sentiment, with the share price at HK$5.19 and a year-to-date share price return of negative 39.72%, although the 3-year total shareholder...
SEHK:6616
SEHK:6616Chemicals

Global New Material International Holdings (SEHK:6616) Revenue Jumps, Is The Premium Valuation Justified?

Why the latest earnings event matters for Global New Material International Holdings Global New Material International Holdings (SEHK:6616) has drawn fresh attention after reporting its half year 2026 earnings, combining sharply higher sales with a swing from profit to loss that leaves investors weighing growth against financial strain. The latest earnings release has landed against a backdrop of strong recent momentum in Global New Material International Holdings. The share price is at...
SEHK:1396
SEHK:1396IT

Greater Bay Area AI Computing Tech (SEHK:1396) Looks Fully Priced After Mixed Earnings

Why Greater Bay Area AI Computing Tech’s Latest Earnings Matter For Investors Greater Bay Area AI Computing Tech (SEHK:1396) reported half year 2026 earnings on August 28, with sales of CNY 2,558.56 million and net income of CNY 275.1 million, alongside sharply lower earnings per share. Greater Bay Area AI Computing Tech’s latest results land after a sharp year to date share price return of 118.38% and a 7 day share price return of 14.50%, even though the 90 day share price return is down...
SEHK:376
SEHK:376Insurance

Could Yunfeng Financial Group (SEHK:376) Be 72% Overvalued On Half Year Earnings?

Why Yunfeng Financial Group Stock Is In Focus After Half Year Earnings Yunfeng Financial Group (SEHK:376) is back on investor radars after reporting half year earnings on 28 August 2026. The group reported net income of HK$632.2 million and basic earnings per share of HK$0.16 from continuing operations. Yunfeng Financial Group’s latest earnings have arrived after a volatile period for the stock, with the share price up 6.56% in the last session and showing a 30-day share price return of...
SEHK:1508
SEHK:1508Insurance

China Reinsurance Group (SEHK:1508) Could Be 24% Undervalued On Half Year Earnings

Half year earnings put China Reinsurance (Group) in focus China Reinsurance (Group) (SEHK:1508) drew fresh attention after reporting half year 2026 earnings. Net income reached CNY 7,187 million with basic and diluted earnings per share from continuing operations at CNY 0.17. China Reinsurance (Group)'s HK$1.275 share price has moved higher over the past quarter, with a 90 day share price return of 7.14%. However, momentum has faded recently, with the 30 day share price return down 6.93% and...
SEHK:966
SEHK:966Insurance

China Taiping Insurance Holdings (SEHK:966) Rallies On H1 Earnings As Its Cheap Valuation Draws Focus

China Taiping Insurance Holdings (SEHK:966) has drawn investor attention after reporting H1 2026 net income of HK$12,872.66 million and basic earnings per share of HK$3.442, both higher than the prior year period. The recent H1 2026 earnings announcement and board appointment appear to have coincided with a sharp pickup in interest around China Taiping Insurance Holdings, with the current share price at HK$21.96. The stock has a 1-day share price return of 3.68% and a 7-day share price return...
SEHK:6881
SEHK:6881Capital Markets

Is China Galaxy Securities (SEHK:6881) Still Cheap Following Strong Half Year 2026 Earnings?

China Galaxy Securities (SEHK:6881) has drawn fresh attention after reporting half year 2026 results, with revenue of CNY 16,850 million and net income of CNY 7,797.06 million, alongside higher earnings per share than a year earlier. The earnings announcement appears to have attracted buyers, with China Galaxy Securities recording a 1 day share price return of 2.41% and a 7 day share price return of 5.29%, even though the year to date share price return is down 22.68%. At the latest share...